Market open · Delayed intraday data · 2:47 PM ET
Last update: Nov 20, 2026, 2:32 PM ET
Boston Scientific Corporation
$42.46▼ 1.23% today
Market Open

Why Boston Scientific Corporation (BSX) stock moved

No significant move on Nov 19, 2026 (−1.5%, close-to-close). Latest notable session: Nov 6, 2026.

Latest session▼ 4.2% · Nov 6, 2026 close

Why Boston Scientific Corporation (BSX) fell 4.2% on November 6, 2026

Boston Scientific Corporation (BSX) fell 4.2% on November 6, 2026, closing at $42.75 versus $44.64 the prior session (close-to-close, from daily closes). Law firm Scott+Scott launches investigation into BSX directors and officers for alleged breach of fiduciary duties. Source: Business Wire.

Updated
Prior close
$44.64
Nov 6, 2026 close
$42.75
Change (close-to-close)
−$1.89
−4.23%
As first detected · Nov 6, 2026, 10:13 AM ET

Law firm Scott+Scott launches investigation into BSX directors and officers for alleged breach of fiduciary duties.

What to watch next: Fiduciary breach investigation raises governance concerns and potential shareholder litigation risk for BSX.

Source: Business Wire · percentages in this note are as captured at detection; the confirmed close-to-close move is shown above.

Earlier sessions that moved BSX

  1. −2.6%After the company cited a cyber disruption that reduced Q3 growth and earnings, and lowered 2026 guidance citing a 2027 trough.
  2. +5.3%Driven by a $455 million co-funding partnership with Blackstone Life Sciences to develop VITALYST, a next-generation miniature heart pump for cardiogenic shock, combined with positive SIMPLAAFY clinical trial data showing lower bleeding risks for the WATCHMAN FLX Pro device (Yahoo Finance).
  3. +5.6%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
  4. −5.8%Boston Scientific slashed earnings guidance following a cyberattack and other operational challenges, as reported by Barron's and The Wall Street Journal. Read the October 28, 2026 analysis →
  5. +3.4%A Scott+Scott Attorneys at Law investor alert regarding a fiduciary duties investigation was published, but this appears to be a routine legal solicitation rather than a new enforcement action or settlement.
  6. −4.1%Following disclosure of a major cybersecurity incident that disrupted order processing and product shipments, prompting management to warn it is unlikely to meet 2026 net sales and earnings guidance.
  7. −5.9%Boston Scientific disclosed a cyberattack that severely disrupted global operations and order processing, prompting management to lower third-quarter and full-year financial guidance on September 8, 2026 (Yahoo Finance). Read the September 8, 2026 analysis →
  8. −2.9%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
  9. +3.1%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
  10. −3.1%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.

Boston Scientific Corporation (BSX) shares fell 1.2% to $42.46 as of November 20, 2026, a modest decline from the prior close of $42.99. BestStocks flagged the session as a major change for BSX. The move is tied to company news. Below, we break down what changed for BSX, why it matters for investors, how the stock reacted, and the catalysts on the calendar.

What happened

Company News

Pomerantz Law Firm initiates investor investigation into Boston Scientific Corporation claims. Legal investigation suggests potential shareholder claims; investors should assess litigation risk and possible financial exposure.

This summary describes the catalyst and move as first detected on Nov 11, 2026, 10:18 AM EST; the stock has continued trading since, so the current price and percentage move (shown above) may be larger or smaller than the figures here.
NewsWeak confidence
Rel. volume
0.4×
Below Avg
Vs peers
—
No comparable peers
Market cap
$61.5B
New York Stock Exchange
Analyst target
$54
+26.6% vs price
Price chart
Nov 20
Not enough price data.
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details

What it means for Boston Scientific Corporation investors

For Boston Scientific Corporation investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Boston Scientific jumped 5.80% to $46.02, driven by a $455 million co-funding partnership with Blackstone Life Sciences to develop VITALYST, a next-generation miniature heart pump for cardiogenic shock, combined with positive SIMPLAAFY clinical trial data showing lower bleeding risks for the WATCHMAN FLX Pro device (Yahoo Finance); Positive price momentum. Weighing against that: Negative session, down 1.2%; Boston Scientific slashed earnings guidance following a cyberattack and other operational challenges, as reported by Barron's and The Wall Street Journal. Wall Street's consensus price target sits at $53.77, implying +26.6% upside from $42.46. Over the past 90 days analysts logged 0 upgrades and 3 downgrades. BestStocks rates the overall signal quality weak (28/100). With earnings roughly 75 days out, the next report is the most likely near-term test of the move.

BSX price reaction

BSX last traded at $42.46, down $0.53 (-1.23%) from the previous close of $42.99. The session traded on 0.4× average volume (below avg), so participation was unremarkable.

Bullish and bearish analyst opinions on Boston Scientific Corporation (BSX)

The consensus analyst price target on Boston Scientific Corporation (BSX) is $53.77, 26.6% above the recent $42.46. Over the past 90 days analysts logged 0 upgrades, 18 maintains, and 3 downgrades. Here is how the bullish and bearish cases on BSX line up.

The bullish case

  • Wall Street's consensus price target of $53.77 implies +26.6% upside from $42.46.
  • The Street's most bullish target is $71.00 (+67.2%).
  • Boston Scientific jumped 5.80% to $46.02, driven by a $455 million co-funding partnership with Blackstone Life Sciences to develop VITALYST, a next-generation miniature heart pump for cardiogenic shock, combined with positive SIMPLAAFY clinical trial data showing lower bleeding risks for the WATCHMAN FLX Pro device (Yahoo Finance).
  • Positive price momentum.

The bearish case

  • 3 analyst downgrades in the past 90 days, most recently TD Cowen to Hold (2026-10-30).
  • Negative session, down 1.2%.
  • Boston Scientific slashed earnings guidance following a cyberattack and other operational challenges, as reported by Barron's and The Wall Street Journal.
Bull vs bear balanceNeutral / Mixed
BearishNeutralBullish

Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.

Analyst price targets and ratings are FMP consensus figures as of Nov 20, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.

Analyst expectations
Consensus target: $54+26.6%
= 18 maintains↓ 3 downgrades
Barclays maintained Equal Weight · 2026-10-30
SEC filings watch
8-K2026-11-17
Material event — review for impact
high
10-Q2026-11-02
Quarterly financial results
medium
8-K2026-10-28
Material event — review for impact
high
8-K2026-10-07
Material event — review for impact
high
Peer context
BSX-1.2%

Previous notable changes for BSX

News2026-11-05
Law firm Scott+Scott launches investigation into BSX directors and officers for alleged breach of fiduciary duties.
Activity2026-11-04via Yahoo Finance ↗
Boston Scientific jumped 5.80% to $46.02, driven by a $455 million co-funding partnership with Blackstone Life Sciences to develop VITALYST, a next-generation miniature heart pump for cardiogenic shock, combined with positive SIMPLAAFY clinical trial data showing lower bleeding risks for the WATCHMAN FLX Pro device (Yahoo Finance). Institutional accumulation—including new positions from First Nebraska Trust Co and Associated Banc Corp—reinforced the rally. Volume of 22.2M shares ran 1.49x average for this time of day.
Filings2026-11-02
Boston Scientific Corporation (BSX) filed a new 10-Q on 2026-11-02, disclosing quarterly financial and operational results.
News2026-11-02
WATCHMAN FLX Pro device met primary endpoints in SIMPLAAFY trial, enabling simplified post-implant drug regimens.
Upcoming catalysts & outlook
Next earnings
2027-02-03 (est.)
in 75 days
Earnings Release
2027-02-03
High impact
Thesis shift
Neutral / Mixed
bearish signal
Risk level
Medium
from change events

Frequently asked questions about BSX

Why did Boston Scientific Corporation (BSX) stock move?

Boston Scientific Corporation (BSX) fell 4.2% on November 6, 2026, closing at $42.75 versus $44.64 the prior session (close-to-close, from daily closes). Law firm Scott+Scott launches investigation into BSX directors and officers for alleged breach of fiduciary duties. Source: Business Wire.

How much did BSX stock fall?

BSX lost 1.23% ($0.53) versus the prior close of $42.99, last trading at $42.46 on 0.4× average volume.

When is Boston Scientific Corporation's next earnings date?

BSX's next earnings report is estimated for 2027-02-03 — about 75 days away.

What is the analyst price target for BSX?

The consensus analyst price target for BSX is $53.77, about 26.6% above the current $42.46. Over the past 90 days, analysts recorded 0 upgrades, 18 maintains, and 3 downgrades.

How BestStocks tracks BSX

This page is generated automatically by BestStocks' change-detection system after company news was detected and verified against independent data sources. It draws on 20 tracked change events for BSX, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 20, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.

Data sources
FMP real-time & historical price dataCompany news feedsSEC EDGAR filingsAnalyst ratings & price targets (FMP)Earnings calendar (FMP)
Educational research tool — not personalized investment advice. Data may be delayed.